Research programme: cationic steroid therapeutics - CSA Biotech/N8 Medical

Drug Profile

Research programme: cationic steroid therapeutics - CSA Biotech/N8 Medical

Alternative Names: Ceragenins; CGX-313; CSA 90; CSA-13; CSA-54; CSA-8; CSAs

Latest Information Update: 24 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Brigham Young University
  • Developer Brigham Young University; Ceragenix Pharmaceuticals; N8 Medical
  • Class Small molecules; Steroids
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections; Fracture
  • Discontinued Methicillin-resistant Staphylococcus aureus infections; Vaccinia; Viral infections

Most Recent Events

  • 04 Mar 2015 Preclinical trials in Fracture in USA before March 2015 (unspecified route)
  • 04 Mar 2015 Pharmacodynamic data from a preclinical trial in Fractures and Bacterial infections released by N8 Medical
  • 09 Oct 2014 Antimicrobial data from a preclinical study in Cystic fibrosis released by N8 Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top